9 completed, 3 recruiting, 1 active not recruiting, 1 unknown. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 9, Recruiting 3, Active not recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Latent Infection: new trials by email Literature Review of Latent Infection trials Research Report on Latent Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV Rifapentine, Isoniazid, Dolutegravir - Tuberculosis | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 144 | 2026-09-28 | 2026-11-02 |
| Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer | Phase 1 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 60 | 2026-06-01 | 2026-11-02 |
| Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Rifapentine, Dolutegravir - Pediatric HIV Infection, Latent Tuberculosis | Phase 1 | Recruiting | Brigham and Women's Hospital | 25 | 2024-11-15 | 2026-07-30 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin rifampicin - Pediatric HIV Infection, Tuberculosis Infection | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2023-07-07 | 2026-07-30 |
| Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years TB/Flu-05E vaccine, Placebo - Tuberculosis Infection | Phase 1 | Completed | Tatyana Zubkova | 51 | 2023-05-10 | 2024-04-18 |
| Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid - Tuberculosis Infection, Isoniazid Adverse Reaction | Phase 1 | Completed | Stanford University | 78 | 2023-03-23 | 2026-06-15 |
| Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Nivaquine ® (Chloroquine) - Tuberculosis Infection | Phase 1 | Unknown | University of Zurich | 16 | 2022-01-04 | 2024-07-01 |
| Tuberculosis Clinical Trials Consortium Study 35 Rifapentine, Isoniazid - Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 69 | 2019-11-12 | 2026-07-24 |
| Doravirine, Rifapentine and Isoniazid Interaction Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH) - Latent Tuberculosis, Human Immunodeficiency Virus | Phase 1 | Completed | Walter K. Kraft | 11 | 2019-04-22 | 2020-03-27 |
| Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA) Tenofovir alafenamide, Rifapentine, Isoniazid (INH) - Healthy Volunteers | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 51 | 2018-06-12 | 2024-08-13 |
| A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456) H56ug/IC31nmol, Placebo - Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis | Phase 1 / Phase 2 | Completed | Aeras | 98 | 2013-08-01 | 2019-12-19 |
| Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis H56:IC31 - Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown | Phase 1 | Completed | Aeras | 25 | 2011-11-01 | 2019-08-21 |
| Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers RUTI, placebo of the vaccine RUTI - Latent Tuberculosis Infection, Tuberculosis | Phase 1 | Completed | Germans Trias i Pujol Hospital | 24 | 2007-04-01 | 2009-05-27 |
Latent Tuberculosis (14) · Acquired Immunodeficiency Syndrome (2) · Tuberculosis (2) · Breast Feeding (1) · HIV Seropositivity (1)
Actinomycetales Infections (14) · Bacterial Infections (14) · Bacterial Infections and Mycoses (14) · Gram-Positive Bacterial Infections (14) · Infections (14) · Mycobacterium Infections (14) · Tuberculosis (12) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · HIV Infections (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · Lentivirus Infections (3)
Isoniazid (8) · rifapentine (7) · Rifampin (3) · dolutegravir (2) · Chloroquine (1) · Drugs, Generic (1) · Ethambutol (1) · Levofloxacin (1) · Pyrazinamide (1) · Pyridoxine (1) · Vitamin B 6 (1) · bedaquiline (1) · doravirine (1) · tenofovir alafenamide (1)
Aeras (2) · Brigham and Women's Hospital (2) · Centers for Disease Control and Prevention (1) · Germans Trias i Pujol Hospital (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institutes of Health Clinical Center (CC) (1) · Stanford University (1) · Tatyana Zubkova (1) · The Aurum Institute NPC (1) · University of Zurich (1) · Walter K. Kraft (1)
South Africa (4) · Nigeria (2) · United States (2) · Botswana (1) · Brazil (1) · Haiti (1) · Indonesia (1) · Kenya (1) · Russia (1) · Spain (1) · Switzerland (1) · Thailand (1) · Uganda (1) · Zimbabwe (1)
Angelique Luabeya, MD (2) · Holly Rawizza, MD, MPH (2) · Anneke Hesseling, MD (1) · Avy Violari, MD (1) · Dereck Tait, MD (1) · Dick Menzies, MD (1) · Dr Vaneshree Govender (1) · Jason R Andrews, MD (1) · Joan Costa, MD, PhD (1) · Joseph A Kovacs, M.D. (1) · Marisa Kaelin, Dr. med. (1) · Mark Cotton, MD (1) · Pere-Joan Cardona, MD, PhD (1) · Walter K Kraft, MD (1)
R21AI172182 (1)